GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vaxcyte Inc (NAS:PCVX) » Definitions » PB Ratio

Vaxcyte (Vaxcyte) PB Ratio : 4.58 (As of Apr. 25, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Vaxcyte PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-04-25), Vaxcyte's share price is $59.55. Vaxcyte's Book Value per Share for the quarter that ended in Dec. 2023 was $13.01. Hence, Vaxcyte's PB Ratio of today is 4.58.

The historical rank and industry rank for Vaxcyte's PB Ratio or its related term are showing as below:

PCVX' s PB Ratio Range Over the Past 10 Years
Min: 0   Med: 0   Max: 8.16
Current: 4.58

During the past 6 years, Vaxcyte's highest PB Ratio was 8.16. The lowest was 0.00. And the median was 0.00.

PCVX's PB Ratio is ranked worse than
74.6% of 1311 companies
in the Biotechnology industry
Industry Median: 2.37 vs PCVX: 4.58

During the past 12 months, Vaxcyte's average Book Value Per Share Growth Rate was 8.40% per year. During the past 3 years, the average Book Value Per Share Growth Rate was 24.30% per year.

During the past 6 years, the highest 3-Year average Book Value Per Share Growth Rate of Vaxcyte was 24.30% per year. The lowest was 24.30% per year. And the median was 24.30% per year.

Back to Basics: PB Ratio


Vaxcyte PB Ratio Historical Data

The historical data trend for Vaxcyte's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vaxcyte PB Ratio Chart

Vaxcyte Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PB Ratio
Get a 7-Day Free Trial - 3.92 4.44 4.00 4.83

Vaxcyte Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.00 3.20 3.27 3.46 4.83

Competitive Comparison of Vaxcyte's PB Ratio

For the Biotechnology subindustry, Vaxcyte's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vaxcyte's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vaxcyte's PB Ratio distribution charts can be found below:

* The bar in red indicates where Vaxcyte's PB Ratio falls into.



Vaxcyte PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Vaxcyte's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Dec. 2023)
=59.55/13.008
=4.58

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Vaxcyte  (NAS:PCVX) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Vaxcyte PB Ratio Related Terms

Thank you for viewing the detailed overview of Vaxcyte's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Vaxcyte (Vaxcyte) Business Description

Traded in Other Exchanges
Address
825 Industrial Road, Suite 300, San Carlos, CA, USA, 94070
Vaxcyte Inc is a vaccine company seeking to improve global health by developing novel vaccines to treat patients suffering from the most common and deadly diseases. Its product comprises. of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-24, VAX-XP, VAX-A1, and VAX-PG.
Executives
Andrew Guggenhime officer: CFO, CBO C/O VAXCYTE, INC., 825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS CA 94070
Grant Pickering director, officer: President & CEO C/O VAXCYTE, INC., 825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS CA 94070
Mikhail Eydelman officer: SVP, Gen Counsel & Corp Sec C/O VAXCYTE, INC., 825 INDUSTRIAL ROAD, SUITE 300, SAN CARLOS CA 94070
Jim Wassil officer: Chief Operating Officer C/O VAXCYTE, INC., 353 HATCH DRIVE, FOSTER CITY CA 94404
Heath Lukatch director 326 BOLLAY DRIVE, GOLETA CA 93117
Elvia Cowan officer: See Remarks Section C/O VAXCYTE, INC., 825 INDUSTRIAL ROAD, SUITE 300, SAN CARLOS CA 94070
Jeff Fairman officer: VP, Research C/O VAXCYTE, INC., 825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS CA 94070
Paul Sauer officer: SVP Process Dev, Manufacturing C/O VAXCYTE, INC., 825 INDUSTRIAL DRIVE, STE. 300, SAN CARLOS CA 94404
Michael E. Kamarck director C/O UNILIFE CORPORATION, 250 CROSS FARM LANE, YORK PA 17406
Carlos V Paya director C/O IMMUNE DESIGN CORP., 1616 EASTLAKE AVE. E, SUITE 310, SEATTLE WA 98102
Harpreet S. Dhaliwal officer: SVP Cml Mfg & Supply Chain C/O VAXCYTE, INC., 825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS CA 94070
Anne S Drapeau director C/O IRON MOUNTAIN INCORPORATED, ONE FEDERAL STREET, BOSTON MA 02110
Teri Loxam director C/O SQZ BIOTECHNOLOGIES COMPANY, 200 ARSENAL YARDS BOULEVARD, SUITE 210, WATERTOWN MA 02472
Jane Wright Mitchell officer: General Counsel C/0 ACELRX PHARMACEUTICALS, INC., 351 GALVESTON DRIVE, REDWOOD CITY CA 94063
Robert Lorne Hopfner director C/O BAY CITY CAPITAL, LLC, 750 BATTERY STREET, SUITE 400, SAN FRANCISCO CA 94111